← FDA DRUG APPROVALS

FDA ANDA · ANDA090631

CARBIDOPA AND LEVODOPA

Sponsor: IMPAX LABS

APPLICATION
ANDA090631
TYPE
ANDA
ORIGINAL APPROVAL
2010-06-08
LATEST ACTION
2010-06-08
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Discontinued

Products

CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 25MG, LEVODOPA 100MG · TABLET, ORALLY DISINTEGRATING · ORAL
CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 25MG, LEVODOPA 250MG · TABLET, ORALLY DISINTEGRATING · ORAL
CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 10MG, LEVODOPA 100MG · TABLET, ORALLY DISINTEGRATING · ORAL

Approval history

2010-06-08OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →